Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, & tolerability of AVP-786 (deudextromethorphan hydrobromide/quinidine sulfate) for agitation treatment in patients w/ dementia of the Alzheimer's type